淋巴结采集套件用于肺癌手术的结局:一项实用性、基于人群、多机构、阶梯式实施研究
该研究在11家医院、1492例肺癌手术患者中阶梯式实施淋巴结采集套件,评估其对病理淋巴结分期质量及围手术期结局的影响。结果显示套件组病理淋巴结分期质量显著提高,围手术期并发症和医疗资源利用无显著差异,且与较低死亡风险相关(粗风险比0.78,95%CI 0.61-0.99)。
要点
- 淋巴结采集套件显著提高病理淋巴结分期质量,75%达到NCCN标准。
- 套件组未检查淋巴结比例0.2%,未检查纵隔淋巴结比例3.2%。
- 套件使用与较低死亡风险相关,粗风险比0.78(95%CI 0.61-0.99)。
核心结论
- 肺癌手术使用淋巴结采集套件显著改善病理淋巴结分期质量,并呈现生存改善趋势,且不增加围手术期并发症或死亡率。
研究设计与样本
- 前瞻性、基于人群、阶梯式实施研究,纳入四个连续医院转诊区域中11家合格医院,共1492例参与者。
- 2014年1月1日至2018年8月28日期间,在三个同质机构队列中实施套件。
- 主要结局为病理淋巴结分期质量,包括检查淋巴结或站数、未检查淋巴结等低质量指标比例及NCCN标准等综合质量基准。
- 次要结局包括围手术期并发症、医疗资源利用和总生存。
主要发现
- 1492例参与者中,56%使用套件切除,44%未使用。
- 套件组无淋巴结检查比例0.2%,非套件组9.8%;无纵隔淋巴结检查比例3.2% vs 25.3%。
- 达到NCCN标准比例套件组75%,非套件组26%(所有比较p < 0.0001)。
- 套件组围手术期并发症或医疗资源利用无差异,但手术时间显著缩短、肺不张比例降低、输血使用略高。
- 套件切除与较低死亡风险相关:粗风险比0.78(95%CI 0.61-0.99),调整后0.85(95%CI 0.71-1.02)。
关键数值与推荐
- 无淋巴结检查比例:套件组0.2% vs 非套件组9.8%。
- 无纵隔淋巴结检查比例:套件组3.2% vs 非套件组25.3%。
- 达到NCCN标准比例:套件组75% vs 非套件组26%(p < 0.0001)。
- 死亡风险:粗风险比0.78(95%CI 0.61-0.99),调整后风险比0.85(95%CI 0.71-1.02)。
临床怎么用
- 肺癌根治性切除术中可考虑使用淋巴结采集套件以提高病理淋巴结分期质量。
- 套件使用不增加围手术期并发症或医疗资源利用,可安全整合入手术流程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Suboptimal pathologic nodal staging prevails after curative-intent resection of lung cancer. We evaluated the impact of a lymph node specimen collection kit on lung cancer surgery outcomes in a prospective, population-based, staggered implementation study. METHODS: From January 1, 2014, to August 28, 2018, we implemented the kit in three homogeneous institutional cohorts involving 11 eligible hospitals from four contiguous hospital referral regions. Our primary outcome was pathologic nodal staging quality, defined by the following evidence-based measures: the number of lymph nodes or stations examined, proportions with poor-quality markers such as nonexamination of lymph nodes, and aggregate quality benchmarks including the National Comprehensive Cancer Network criteria. Additional outcomes included perioperative complications, health care utilization, and overall survival. RESULTS: Of 1492 participants, 56% had resection with the kit and 44% without. Pathologic nodal staging quality was significantly higher in the kit cases: 0.2% of kit cases versus 9.8% of nonkit cases had no lymph nodes examined; 3.2% versus 25.3% had no mediastinal lymph nodes; 75% versus 26% attained the National Comprehensive Cancer Network criteria (p < 0.0001 for all comparisons). Kit cases revealed no difference in perioperative complications or health care utilization except for significantly shorter duration of surgery, lower proportions with atelectasis, and slightly higher use of blood transfusion. Resection with the kit was associated with a lower hazard of death (crude, 0.78 [95% confidence interval: 0.61-0.99]; adjusted 0.85 [0.71-1.02]). CONCLUSIONS: Lung cancer surgery with a lymph node collection kit significantly improved pathologic nodal staging quality, with a trend toward survival improvement, without excessive perioperative morbidity or mortality.
引用
- Osarogiagbon RU, Smeltzer MP, Faris NR, et al. Outcomes After Use of a Lymph Node Collection Kit for Lung Cancer Surgery: A Pragmatic, Population-Based, Multi-Institutional, Staggered Implementation Study. J Thorac Oncol. 2021. PMID: 33607311. doi:10.1016/j.jtho.2020.12.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。